who knows what will come next from prr.we've had a period of 8...

who knows what will come next from prr.we've had a period of 8 weeks where prr has turned from a relatively high risk play due to lack of funds to a company that is on the verge of huge things.we were sitting at .005 and have risen to 11c and now we have settled at the 6c level awaiting the next move.in the 8 week period we've had the following happen.

1.Commencement of CVac Cancer Therapy Patient Treatment

2.Secures $12M Commercialisation Funding through fortrend.

3.Second European Patent for CVac Ovarian Cancer Treatment.

4.Chinese Patent for Oncomab Cancer Antibody Treatment.

5.Secured $1.5 million in funding from laurence freedman.

6.dendreon has through successful phase111 FDA trials for provenge cleared a path for prima's CVAC.


ok now whats next.

clearly the market awaits prr's next move.we have the spp that everyone is awaiting.secondly and more importantly prr awaits the granting of the Investigational New Drug status.this is the big step that will get bigger players,brokers and institutions looking at prr.this should happen within the next 4-8 weeks and i hope should propel prr to a market cap between the 50>100 mill mark.this is when the brokers will start looking at and recommending prr with the possibilities of cvac being taken out by a bigger player.

between now and then who knows what prr have up their sleeve but as announced with the Chinese patent:Prima is currently in negotiations to secure a major pharmaceutical co-developmentpartner to bring Cripto-1 into commercialisation.this could happen any day.

and dont forget there is always the possibility that cvac is already being looked at by a bigger player wanting to swoop.in the last update we had the corparate development update that suggested the possible partnering of cvac as follows:

Corporate Development
Prima will update the market as further information becomes available, and it is the consistent commitment of the board and management to take every opportunity to generate and maximise wealth for the company and its investors.
The company intends principally to do this via the pursuit of a US FDA IND for CVacTM and successful partnering of the future clinical trials.

my feeling here is that prr if they get the opportunity to sell cvac at a good price as well as retain a royalty they will look to do this as firstly it benefits shareholders in taking away the risks of taking cvac to market and secondly a bigger u.s company could bring it to market much quicker to the benefit of sufferers of ovarian cancer.